La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne que se llevó a cabo el pasado día 7 de Septiembre de 2017, día Mundial de dicha enfermedad. Las sesiones tuvieron lugar en el Aula de Grados de la Facultad de Biología de la UB, y en las…
II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
posted on September 4, 2017
SOM Biotech licenses its first product and expands to the United States
posted on July 25, 2017
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2…
SOM Biotech at the 2017 New York Venture Summit
posted on July 17, 2017
SOM Biotech was selected to present at the 2017 New York Venture Summit in front of more than 100 top tier VCs, Corporate VCs and Angel Investors. New York, July 18th-19th, 2017. Dr. Raúl Insa, SOM Biotech CEO, and Michael Greenberg, VP Business Development, were attending this relevant financing event. Further information at NY Venture Summit…
21st Summer School of the University of Barcelona
posted on July 11, 2017
Dr. Raúl Insa, SOM Biotech CEO, was invited to the 21st Summer School of the University of Barcelona to make a Lecture on Drug Repurposing in rare diseases. The 1-week course was entitled "Rare Diseases, from patient to its cure". Dr. Insa had the opportunity to explain the audience SOM Biotech's Business model and how the company 'merges' these two…
9th Summer School on Medicines
posted on July 5, 2017
Dr. Raúl Insa, SOM Biotech CEO, was the invited speaker at Closing Session of 9th Summer School on Medicines (SSM9). This event took place in Barcelona from 2 to 7 July 2017. SSM9 is structured to cover the whole process that leads from ideas and projects to drugs reaching the market, including visits to research centers…
SOM Biotech closed €2M funding round and opens €10M Series A
posted on June 27, 2017
SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 different countries participated such as Monaco, Poland, UK, USA, India and South Korea among others. Most of the super-business angels involved include former pharmaceutical executives, which shows trust in SOM’s business model and its future vision. Additionally, SOM Biotech opened…